IL318907A - Treatment of lupus using human anti-CZCR5 antibodies - Google Patents

Treatment of lupus using human anti-CZCR5 antibodies

Info

Publication number
IL318907A
IL318907A IL318907A IL31890725A IL318907A IL 318907 A IL318907 A IL 318907A IL 318907 A IL318907 A IL 318907A IL 31890725 A IL31890725 A IL 31890725A IL 318907 A IL318907 A IL 318907A
Authority
IL
Israel
Prior art keywords
seq
antibody
patients
sar113244
amino acid
Prior art date
Application number
IL318907A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Priority claimed from PCT/EP2018/057310 external-priority patent/WO2018172465A1/en
Publication of IL318907A publication Critical patent/IL318907A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL318907A 2017-03-22 2018-03-22 Treatment of lupus using human anti-CZCR5 antibodies IL318907A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475173P 2017-03-22 2017-03-22
EP17306079 2017-08-18
PCT/EP2018/057310 WO2018172465A1 (en) 2017-03-22 2018-03-22 Treatment of lupus using humanized anti-cxcr5 antibodies

Publications (1)

Publication Number Publication Date
IL318907A true IL318907A (en) 2025-04-01

Family

ID=61827719

Family Applications (2)

Application Number Title Priority Date Filing Date
IL318907A IL318907A (en) 2017-03-22 2018-03-22 Treatment of lupus using human anti-CZCR5 antibodies
IL26941919A IL269419A (en) 2017-03-22 2019-09-18 Treatment of lupus using humanized anti-cxcr5 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL26941919A IL269419A (en) 2017-03-22 2019-09-18 Treatment of lupus using humanized anti-cxcr5 antibodies

Country Status (7)

Country Link
US (1) US20240207397A1 (https=)
EP (1) EP3601344A1 (https=)
JP (3) JP2020514386A (https=)
KR (2) KR20190131068A (https=)
CN (1) CN110662767A (https=)
AU (1) AU2018238540B2 (https=)
IL (2) IL318907A (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023010483A1 (en) * 2021-08-05 2023-02-09 Hifibio (Hk) Limited Anti-human cxcr5 antibody and uses thereof
WO2021216505A1 (en) * 2020-04-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cxcl13 gene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909273B (zh) * 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
AU2015305850A1 (en) * 2014-08-22 2017-04-06 Sorrento Therapeutics, Inc. Antigen binding proteins that bind CXCR5

Also Published As

Publication number Publication date
IL269419A (en) 2019-11-28
KR20250052493A (ko) 2025-04-18
JP2025087764A (ja) 2025-06-10
EP3601344A1 (en) 2020-02-05
JP2023040241A (ja) 2023-03-22
AU2018238540A1 (en) 2019-11-07
JP2020514386A (ja) 2020-05-21
CN110662767A (zh) 2020-01-07
KR20190131068A (ko) 2019-11-25
US20240207397A1 (en) 2024-06-27
AU2018238540B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
JP5926162B2 (ja) 炎症傷害の処置および評価
CA2670288C (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
EP3237447B1 (en) Anti-csf1r antibodies for treating pvns
JP2020019811A (ja) 抗ｖｌａ−４抗体
JP2008544960A5 (https=)
JP2025087764A (ja) ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置
JP2010132660A (ja) 多発性硬化症を治療する方法
JP2022539785A (ja) ＴＡＣＩ－Ｆｃ融合タンパク質及びその用途
CN106794255A (zh) 使用针对cd28的域抗体治疗系统性红斑狼疮的方法
WO2015138337A1 (en) Compositions and methods for treating rheumatoid arthritis
US20210077619A1 (en) Treatment of lupus using humanized anti-cxcr5 antibodies
US20250276059A1 (en) Therapeutic methods and agents for the treatment of myocardial infarction
US20160002326A1 (en) Compositions and methods for treating rheumatoid arthritis
JP2024505563A (ja) Ｇｉｔｒアンタゴニスト及びその使用方法
EP4583913A1 (en) Subcutaneous dosing of anti-cd38 antibodies for treating patients with moderate to severe systemic lupus erythematosus
CN121909046A (zh) 脱发病症的治疗
HK40005884B (en) Anti-vla-4 antibodies
HK1242339B (en) Anti-vla-4 antibodies